Trial Profile
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Acronyms EPICS
- Sponsors Zydus Discovery DMCC
- 03 Sep 2021 Results published in the Journal of Hepatology
- 03 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Dec 2020 According to a Zydus Cadila media release, results of this study were presented earlier at The Liver Meeting 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).